Live
Endpoints NewsAgios licenses Oscotec drug; CEPI funds three potential Ebola vaccinesPromega BlogAdvancing Canine Cancer Immunotherapy through One Health Comparative Oncology ResearchEndpoints News#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T updateEndpoints NewsAfter being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listingFierceBiotechRallybio swerves past Candid pothole to land deal with cancer drug developer AvenzoFierceBiotechAgios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 studyPharmaVoiceAstraZeneca aims for a new blockbuster run in cardio diseaseFierceBiotechServier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipelineBioWorldDeep Apple Therapeutics synthesizes GIPR antagonistsBioWorldHIV integrase inhibitors divulged in MSD patentBioWorldMuna Therapeutics discloses TREM2 agonistsBioWorldArmy Medical University reports new cGAS/STING pathway inhibitors
eLife Feb 5, 2026

Ly6G<sup>+</sup> granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis

Ly6G + granulocytes-derived IL-17 limits protective host responses and promotes tuberculosis pathogenesis

Original
Body unavailable. Use the original source.